 Diabetes Care. 2018;41(2):258–66. 9. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardio- vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. 10. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2–3):153–214. 11. Graaf CD, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013. 12. Buckley ST, Sche´ele SG, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide [poster]. Diabetes. 2017;66(Suppl 1):1206-P. 13. Connor A, Borregaard J, Buckley ST, et al. Site of absorption of an oral formulation of semaglutide [poster]. Diabetes. 2017;66(Suppl 1):1180-P. 14. Davies M, Pieber TR, Hartoft-Nielsen M-L, Hansen OKH, Jab- bour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–70. 15. Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381–90. 16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. 17. DuBois D, DuBois EF. 